Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) declared that John H. Johnson, Chief Executive Officer and President of Savient will inaugurate the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 10:30 AM Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company aimed at developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed global rights to the technology related to KRYSTEXXA along with its uses from Duke University (“Duke”) and Mountain View Pharmaceuticals, Inc. (“MVP”).
Duke developed the recombinant uricase enzyme and MVP developed the Pegylation technology used in the fabrication of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology along with Savient owns or co-owns U.S. and foreign patents and patent applications which collectively form an extensive portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.
For further information, visit the link.
